Know Cancer

or
forgot password

Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage


N/A
50 Years
74 Years
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage


This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to
review whether PSA velocity (change over time) will predict the presence of prostate cancer
and its grade and stage (severity) by two year biopsy. The investigator will review and
compare data to a previously published study of similar design with finasteride.


Inclusion Criteria:



- Men,

- 50-74 years old with elevated PSA (>=4) along with negative entry biopsy of the
prostate who had a subsequent biopsy by 24 months.

Exclusion Criteria:

- Any positive biopsy of the prostate indicative of cancer upon entry

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Retrospective

Principal Investigator

Steven I Cohen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Urological Associates Inc.

Authority:

United States: Institutional Review Board

Study ID:

8DUT115799

NCT ID:

NCT01484808

Start Date:

January 2012

Completion Date:

May 2012

Related Keywords:

  • Prostate Cancer
  • PSA Density
  • Prostate Cancer
  • Prostate Biopsy
  • PSA
  • Prostatic Neoplasms

Name

Location

Division of Urology, Brown UniversityProvidence, Rhode Island  02903